{"product_id":"biolegend-108910","title":"Biolegend, 108910, APC anti-mouse CD49b (pan-NK cells) Antibody, 100μg","description":"\u003cp\u003eDX5 antigen has been recently characterized as CD49b. It is a 150 kD integrin α chain also known as α 2 integrin, VLA-2 α chain, and integrin α 2 chain. CD49b non-covalently associates with CD29 (β 1 integrin) to form the CD49b\/CD29 complex known as VLA-2, a receptor for collagen and laminin. CD49b is expressed on platelets, the majority of NK cells, NKT cells, and a small subset of CD8+ T cells (this population can be significantly increased following viral infection). DX5 is used for the identification and isolation of NK cells, and is especially useful for identifying NK cells in mice lacking the NK1.1 antigen.\u003cbr\u003e\n100μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: IL-2-propagated NK1.1+ cells from C57BL\/6 mice\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified with APC under optimal conditions, and is at \u0026gt;85% purity.\u003cbr\u003e\nConcentration: 0.2 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nExcitation Laser: Red Laser (633 nm)\u003cbr\u003e\nApplication Notes: The DX5 clone detects cells expressing relatively high levels of CD49b and may not be useful for the detection of cells expressing low levels of CD49b. DX5 does not block NK cell killing or binding to collagen in vitro. Additional reported applications (for the relevant formats) include: complement-mediated cytotoxicity2 and immunohistochemical staining5 of formalin-fixed and paraffin-embedded tissue sections as well as immunohistochemical staining of acetone-fixed frozen sections10. The binding of DX5 antibody to splenic NK cells can be blocked by HMa2 antibody.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Arase H, et al. 2001. J. Immunol. 167:1141. (FC) Sepulveda H, et al. 1999. J. Immunol. 163:1133. Norian LA and Allen PM. 2004. J. Immunol. 173:835. (FC) Andoniou CE, et al. 2005. Nature Immunology 6:1011. Oertelt S, et al. 2006. J. Immunol. 177:1655. (IHC) PubMed Bourdeau A, et al. 2007. Blood doi:10.1182\/blood-2006-08-044370. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed Qui Q, et al. 2010. J. Immunol. 184:1681. (FC) PubMed Busche A, et al. 2011. J. Immunol. 186:2918. PubMed Kim HR, et al. 2011. Nephrology 16:545. (IHC) PubMed Seyoum B, et al. 2011. Vaccine. 29:8002. PubMed Younos IH, et al. 2012. Int Immunopharmacol. 13:245. PubMed Honjo K, et al. 2012. PNAS. PubMed. Huang HN, et al. 2013. Biomaterials. 34:10151. PubMed\u003cbr\u003e\nProduct Citations: del Rio ML, et al. 2023. Front Immunol. 14:1113858. PubMed Rabia E, et al. 2023. Front Immunol. 14:1168444. PubMed Aghayev T, et al. 2022. Cancer Discov. 12:1960. PubMed del Rio ML, et al. 2022. Front Immunol. 13:887348. PubMed Mandour MF, et al. 2023. Front Med (Lausanne). 9:1057252. PubMed Ludwik KA, et al. 2020. Cell Reports. 32(3):107931. PubMed Thi VAD, et al. 2019. Mol Cells. 42:869. PubMed Page N, et al. 2018. Immunity. 48:937. PubMed Yang C, et al. 2021. J Immunother Cancer. 9:. PubMed del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed Chen J, et al. 2022. J Nanobiotechnology. 20:283. PubMed Yoon Y, et al. 2021. Cancers (Basel). 13: . PubMed Best SA, et al. 2018. Cell Metab. 27:935. PubMed Seyoum B, et al. 2011. Vaccine. 29:8002. PubMed Shan M et al. 2018. Immunity. 49(4):709-724 . PubMed Fujita K, et al. 2019. Proc Natl Acad Sci U S A. 116:14714. PubMed Ho V, et al. 2016. PLoS One. 11:e0168072. PubMed JI B, et al. 2016. Cell Death Differ. 23:759-75. PubMed Ludwik KA, et al. 2021. STAR Protocols. 2(1):100270. PubMed Niemann J, et al. 2019. Nat Commun. 10:3236. PubMed , et al. 2021. Eur J Immunol. 51:2708. PubMed LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed Hu J, et al. 2019. Mol Ther Nucleic Acids. 16:650. PubMed Rohner L, et al. 2020. Sci Rep. 0.570833333. PubMed Cohen M, et al. 2010. J Immunol. 185:5869. PubMed Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed Liu Z, et al. 2020. Cell. 178(6):1509-1525.e19.. PubMed Denny JE, et al. 2019. Sci Rep. 2.786111111. PubMed Ye Y, et al. 2017. Sci Immunol. 2:17. PubMed Gentek R, et al. 2018. Immunity. 48:1160. PubMed Zhou J, et al. 2022. Int J Oncol. 61: . PubMed Mandour MF, et al. 2020. Infect Agent Cancer. 15:30. PubMed Do-Thi VA, et al. 2021. Cancers (Basel). 13:. PubMed Bell CR, et al. 2022. Nat Commun. 13:2063. PubMed Tassi I, et al. 2014. J Immunol. 193:4303. PubMed Jee JJ, et al. 2022. Nat Commun. 13:18. PubMed Kim S, et al. 2022. Cancers (Basel). 14:. PubMed Bonavita E, et al. 2020. Immunity. 1215:53. PubMed Pelly V, et al. 2016. Mucosal Immunol. 10.1038\/mi.2016.4. PubMed Jovicic N, et al. 2015. PLoS One. 10: 0134089. PubMed Braza MS et al. 2018. Immunity. 49(5):819-828 . PubMed Barsoumian HB, et al. 2022. Cancers (Basel). 14:. PubMed Liu X, et al. 2021. Adv Sci (Weinh). 8:e2100233. PubMed Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed Liu Z, et al. 2020. STAR Protoc. 1:100029. PubMed Honjo K, et al. 2012. Proc Natl Acad Sci U S A. 109:15882. PubMed Younos I, et al. 2012. Int Immunopharmacol. 13:245. PubMed Pinto AR, et al. 2012. PLoS One. 7:e36814. PubMed\u003cbr\u003e\nRRID: AB_313416 (BioLegend Cat. No. 108909) AB_313417 (BioLegend Cat. No. 108910)\u003cbr\u003e\nStructure: Integrin α chain, 150 kD\u003cbr\u003e\nDistribution: NK cells, subset of T cells\u003cbr\u003e\nFunction: Adhesion\u003cbr\u003e\nLigand\/Receptor: Collagen, laminin\u003cbr\u003e\nCell Type: NK cells, T cells\u003cbr\u003e\nBiology Area: Cell Adhesion, Cell Biology, Immunology, Innate Immunity\u003cbr\u003e\nMolecular Family: Adhesion Molecules, CD Molecules\u003cbr\u003e\nAntigen References: 1. Arase H, et al. 2001. J. Immunol. 167:1141. 2. Barclay AN, et al. 1997. The Leukocyte Antigen FactsBook Academic Press. 3. Sasaki K, et al. 2003. Int. Immunol. 15:701. 4. Inoue O, et al. 2003. J. Cell Biol. 160:769.\u003cbr\u003e\nGene ID: 16398\u003cbr\u003e\nUniProt: View information about CD49b on UniProt.org\u003cbr\u003e\nClone: DX5\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: α2 integrin, VLA-2 α chain, DX5, Integrin α2 chain, ITGA2\u003cbr\u003e\nIsotype: Rat IgM, κ\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46863061876905,"sku":"108910","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/ar\/products\/biolegend-108910","provider":"Iright","version":"1.0","type":"link"}